MUC1 immunotherapy

被引：95

作者：

Beatson, Richard E. ^{[1
]}

Taylor-Papadimitriou, Joyce ^{[1
]}

Burchell, Joy M. ^{[1
]}

机构：

[1] Kings Coll London, Guys Hosp, Breast Canc Biol Grp, London SE1 9RT, England

来源：

IMMUNOTHERAPY | 2010年 / 2卷 / 03期

关键词：

aberrant O-linked glycosylation; cancer; episialin; immunotherapy; MUC1; polymorphic epithelial mucin; BREAST-CANCER PATIENTS; HUMORAL IMMUNE-RESPONSE; CYTOTOXIC T-LYMPHOCYTES; TUMOR-ASSOCIATED MUC1; SQUAMOUS-CELL CARCINOMA; O-LINKED GLYCOSYLATION; PULSED DENDRITIC CELLS; GROWTH-FACTOR RECEPTOR; PHASE-I TRIAL; C-TYPE LECTIN;

D O I：

10.2217/IMT.10.17

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.

引用

页码：305 / 327

页数：23

共 228 条

[1] Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo [J].

Accapezzato, D ;

Visco, V ;

Francavilla, V ;

Molette, C ;

Donato, T ;

Paroli, M ;

Mondelli, MU ;

Doria, M ;

Torrisi, MR ;

Barnaba, V .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (06) :817-828

[2]

Acres B, 2007, J BUON, V12, pS71

[3] Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 [J].

Agrawal, B ;

Krantz, MJ ;

Reddish, MA ;

Longenecker, BM .

NATURE MEDICINE, 1998, 4 (01) :43-49

[4]

AGRAWAL B, 1995, CANCER RES, V55, P2257

[5] The expression of MUC1 in human Fallopian tube during the menstrual cycle and in ectopic pregnancy [J].

Al-Azemi, M. ;

Refaat, B. ;

Aplin, J. ;

Ledger, W. .

HUMAN REPRODUCTION, 2009, 24 (10) :2582-2587

[6] Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution [J].

Alajez, NM ;

Schmielau, J ;

Alter, MD ;

Cascio, M ;

Finn, OJ .

BLOOD, 2005, 105 (12) :4583-4589

[7] New rationales for using TGFβ inhibitors in radiotherapy [J].

Andarawewa, Kumari L. ;

Paupert, Jenny ;

Pal, Anupama ;

Barcellos-Hoff, Mary Helen .

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2007, 83 (11-12) :803-811

[8] Tumor-derived exosomes:: a new source of tumor rejection antigens [J].

André, F ;

Scharz, NEC ;

Chaput, N ;

Flament, C ;

Raposo, G ;

Amigorena, S ;

Angevin, E ;

Zitvogel, L .

VACCINE, 2002, 20 :A28-A31

[9] A glycopeptide in complex with MHC class I uses the GaINAc residue as an anchor [J].

Apostolopoulos, V ;

Yuriev, E ;

Ramsland, PA ;

Halton, J ;

Osinski, C ;

Li, WJ ;

Plebanski, M ;

Paulsen, H ;

McKenzie, IFC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (25) :15029-15034

[10] Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses [J].

Apostolopoulos, V ;

Barnes, N ;

Pietersz, GA ;

McKenzie, IFC .

VACCINE, 2000, 18 (27) :3174-3184

← 1 2 3 4 5 6 7 8 9 10 →